Narcolepsy - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2016, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 2, 3 and 3 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Narcolepsy.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Narcolepsy Overview 8
Therapeutics Development 9
Pipeline Products for Narcolepsy - Overview 9
Pipeline Products for Narcolepsy - Comparative Analysis 10
Narcolepsy - Therapeutics under Development by Companies 11
Narcolepsy - Therapeutics under Investigation by Universities/Institutes 12
Narcolepsy - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Narcolepsy - Products under Development by Companies 16
Narcolepsy - Products under Investigation by Universities/Institutes 17
Narcolepsy - Companies Involved in Therapeutics Development 18
Bioprojet SCR 18
Evotec AG 19
Flamel Technologies S.A. 20
H.A.C. Pharma 21
Heptares Therapeutics Limited 22
Jazz Pharmaceuticals Plc 23
NLS Pharma Group 24
Ono Pharmaceutical Co., Ltd. 25
Sanofi 26
SK Biopharmaceuticals Co., Ltd. 27
Taisho Pharmaceutical Holdings Co., Ltd. 28
Theranexus SAS 29
Narcolepsy - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 37
Drug Profiles 38
(flecainide acetate + modafinil) - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
arbaclofen - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
JZP-386 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
mazindol - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
mazindol - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
NLS-3 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ONO-4127 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Pentylenetetrazol - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
pitolisant - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
SAR-110068 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SKL-N05 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Agonize Orexin Receptor for EDS and Narcolepsy - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
sodium oxybate - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
sodium oxybate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
TS-091 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Narcolepsy - Dormant Projects 62
Narcolepsy - Discontinued Products 63
Narcolepsy - Product Development Milestones 64
Featured News & Press Releases 64
Oct 06, 2016: Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218 64
Oct 04, 2016: Theranexus Has Obtained an Orphan Drug Designation from the FDA for THN102 in the Treatment of Narcolepsy 64
Jul 11, 2016: Mazindol Granted Orphan Drug Designation in the US & Europe for Treatment of Narcolepsy 65
Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting 65
May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness 66
Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate 67
Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep 67
Nov 20, 2015: Narcolepsy treatment recommended for approval 68
Oct 19, 2015: Theranexus: Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders, in partnership with the French Armed Forces Biomedical Research Institute (IRBA) 69
Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies 69
Jun 04, 2015: Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem(sodium oxybate) at SLEEP 2015 70
May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 71
Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate 71
Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 72
Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for Narcolepsy, H2 2016 9
Number of Products under Development for Narcolepsy - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Narcolepsy - Pipeline by Bioprojet SCR, H2 2016 18
Narcolepsy - Pipeline by Evotec AG, H2 2016 19
Narcolepsy - Pipeline by Flamel Technologies S.A., H2 2016 20
Narcolepsy - Pipeline by H.A.C. Pharma, H2 2016 21
Narcolepsy - Pipeline by Heptares Therapeutics Limited, H2 2016 22
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H2 2016 23
Narcolepsy - Pipeline by NLS Pharma Group, H2 2016 24
Narcolepsy - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 25
Narcolepsy - Pipeline by Sanofi, H2 2016 26
Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 27
Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 28
Narcolepsy - Pipeline by Theranexus SAS, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 37
Narcolepsy - Dormant Projects, H2 2016 62
Narcolepsy - Discontinued Products, H2 2016 63